Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 380 participants.

Also called NCT05630586

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 380 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05630586
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05630586. Randomized; single masking; primary purpose treatment. Start 2023-04-12 (actual); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
Acronym
ASSET
Condition
Acute Ischemic Stroke
Intervention (Drug)
Semaglutide
Intervention (Other)
Standard care
Lead sponsor
Aarhus University Hospital (class: other)
Collaborator
Bispebjerg Hospital (class: other)
Collaborator
Glostrup University Hospital, Copenhagen (class: other)
Collaborator
Odense University Hospital (class: other)
Collaborator
Herning Hospital (class: other)
Collaborator
Aalborg University Hospital (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct05630586
Content hash
699340d8b3a8dbac5258f8aeb71b3f2ce2b592556cbc565dfc74b805e9943b36